Association of IGF-I and IGFBP-3 with health care costs and hospitalization: Results from a prospective observational study

Growth Hormone and IGF Research

Volumn 21, Issue 2, 2011, Pages 89-95

  Baumeister, Sebastian E ^a   Friedrich, Nele ^a   Schmidt, Carsten Oliver ^a   Völzke, Henry ^a   Nauck, Matthias ^a   Hoffmann, Wolfgang ^a   Fleßa, Stefan ^a   Marschall, Paul ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Health care cost; Hospitalization; IGF I; IGFBP 3

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SELF REPORT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79955464177     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.02.001     Document Type: Article

References (42)

1. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
2. Colao A., Ferone D., Marzullo P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 2004, 25:102-152.
3. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 2008, 93:61-67.
4. Stochholm K., Gravholt C.H., Laursen T., et al. Mortality and GH deficiency: a nationwide study. Eur. J. Endocrinol. 2007, 157:9-18.
5. Moock J., Albrecht C., Friedrich N., et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur. J. Endocrinol. 2009, 160:17-24.
6. Laughlin G.A., Barrett-Connor E., Criqui M.H., et al. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2004, 89:114-120.
7. Roubenoff R., Parise H., Payette H.A., et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am. J. Med. 2003, 115:429-435.
8. Friedrich N., Haring R., Nauck M., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 2009, 94:1732-1739.
9. van Bunderen C.C., van Nieuwpoort I.C., van Schoor N.M., et al. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J. Clin. Endocrinol. Metab. 2010, 95:4616-4624.
10. Juul A., Scheike T., Davidsen M., et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
11. Vasan R.S., Sullivan L.M., D'Agostino R.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med. 2003, 139:642-648.
12. Friedrich N., Rosskopf D., Brabant G., et al. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the Study of Health in Pomerania (SHIP). Exp. Clin. Endocrinol. Diabetes 2010, 118(4):266-273.
13. Heald A.H., Cruickshank J.K., Riste L.K., et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44:333-339.
14. Sesti G., Sciacqua A., Cardellini M., et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diab. Care 2005, 28:120-125.
15. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
16. Samani A.A., Yakar S., LeRoith D., et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
17. Clayton P.E., Banerjee I., Murray P.G., et al. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat. Rev. Endocrinol. 2011, 7(1):11-24.
18. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin. Endocrinol. Oxf. 2008, 69:347-358.
19. Ehrnborg C., Hakkaart-Van Roijen L., Jonsson B., et al. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000, 17:621-628.
20. Sanmarti A., Lucas A., Hawkins F., et al. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group. Eur. J. Endocrinol. 1999, 141:481-489.
21. Völzke H., Alte D., Schmidt C.-O., et al. Cohort Profile: The Study of Health in Pomerania (SHIP). Int J Epi in print.
22. Graf von der Schulenburg J.M., Greiner W., Jost F., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544.
23. Krauth C., Hessel F., Hansmeier T., et al. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation - Ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation [Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 2005, 67:736-746.
24. Federation German Hospital A Survey of Hospital Planing and Investment Financing in the German Federal States [Bestandsaufnehme zur Krankenhausplanung und Investitionsfinanzierug in den Bundesländern] http://www.dkgev.de.
25. Kawachi I., Kennedy B.P. The relationship of income inequality to mortality: does the choice of indicator matter?. Soc. Sci. Med. 1997, 45:1121-1127.
26. Friedrich N., Alte D., Völzke H., et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm. IGF Res. 2008, 18:228-237.
27. Stevens L.A., Coresh J., Greene T., et al. Assessing kidney function-measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006, 354:2473-2483.
28. Manning W.G. The logged dependent variable, heteroscedasticity, and the retransformation problem. J. Health Econ. 1998, 17:283-295.
29. Localio A.R., Margolis D.J., Berlin J.A. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J. Clin. Epidemiol. 2007, 60:874-882.
30. Fishman P.A., Goodman M.J., Hornbrook M.C., et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med. Care 2003, 41:84-99.
31. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
32. Hogan J.W., Roy J., Korkontzelou C. Handling drop-out in longitudinal studies. Stat. Med. 2004, 23:1455-1497.
33. Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat. Med. 2000, 19:1831-1847.
34. Newhouse J.P., Manning W.G., Keeler E.B., et al. Adjusting capitation rates using objective health measures and prior utilization. Health Care Financ. Rev. 1989, 10:41-54.
35. Powers C.A., Meyer C.M., Roebuck M.C., et al. Predictive modeling of total healthcare costs using pharmacy claims data: a comparison of alternative econometric cost modeling techniques. Med. Care 2005, 43:1065-1072.
36. Hakkaart-van Roijen L., Beckers A., Stevenaert A., et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998, 14:395-403.
37. Hietaniemi M., Poykko S.M., Ukkola O., et al. IGF-I concentrations are positively associated with carotid artery atherosclerosis in women. Ann. Med. 2005, 37:373-382.
38. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 2003, 13:113-170.
39. Hulka B.S., Wheat J.R. Patterns of utilization. The patient perspective. Med. Care 1985, 23:438-460.
40. Pescosolido B.A., Levy A.L. The role of social networks in health, illness, disease and healing: the accepting present, the forgotten past, and the dangerous potential for a complacent future. Soc. Netwoks Health 2002, 8:3-25.
41. Jankowska E.A., Biel B., Majda J., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006, 114:1829-1837.
42. Morgentaler A. Commentary: guideline for male testosterone therapy: a clinician's perspective. J. Clin. Endocrinol. Metab. 2007, 92:416-417.